Sequential design approaches for bioequivalence studies with crossover designs.
The planning of bioequivalence (BE) studies, as for any clinical trial, requires a priori specification of an effect size for the determination of power and an assumption about the variance. The specified effect size may be overly optimistic, leading to an underpowered study. The assumed variance can be either too small or too large, leading, respectively, to studies that are underpowered or overly large. There has been much work in the clinical trials field on various types of sequential designs that include sample size reestimation after the trial is started, but these have seen only little use in BE studies. The purpose of this work was to validate at least one such method for crossover design BE studies. Specifically, we considered sample size reestimation for a two-stage trial based on the variance estimated from the first stage. We identified two methods based on Pocock's method for group sequential trials that met our requirement for at most negligible increase in type I error rate.
Potvin
Diane
D
Theratechnologies Inc., Montréal, Québec, Canada.
DiLiberti
Charles E
CE
Hauck
Walter W
WW
Parr
Alan F
AF
Schuirmann
Donald J
DJ
Smith
Robert A
RA
D002626:Chemistry, Pharmaceutical / Q000379:methods / Q000592:standards; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D018592:Cross-Over Studies; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism*; D012107:Research Design / Q000592:standards; D013810:Therapeutic Equivalency
D004364:Pharmaceutical Preparations